Evidence map›Paper›PMID 32860726›Full record

ArticleAging cell2020

Similar burden of pathogenic coding variants in exceptionally long-lived individuals and individuals without exceptional longevity.

Danielle Gutman, Gabriel Lidzbarsky, Sofiya Milman, Tina Gao, Patrick Sin-Chan, Claudia Gonzaga-Jauregui, Regeneron Genetics Center, Joris Deelen, Alan R Shuldiner, Nir Barzilai and 1 more

Open access · goldAbstract read
In one paragraph

Article in Aging cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Danielle GutmanFaculty of Natural Sciences, University of Haifa, Haifa, Israel.ORCID 0000-0001-9761-580X
Gabriel LidzbarskyFaculty of Natural Sciences, University of Haifa, Haifa, Israel.
Sofiya MilmanDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Tina GaoDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Patrick Sin-ChanRegeneron Genetics Center, Tarrytown, New York, USA.
Claudia Gonzaga-JaureguiRegeneron Genetics Center, Tarrytown, New York, USA.
Regeneron Genetics CenterRegeneron Genetics Center, Tarrytown, New York, USA.
Joris DeelenMax Planck Institute for Biology of Ageing, Cologne, Germany.
Alan R ShuldinerRegeneron Genetics Center, Tarrytown, New York, USA.
Nir BarzilaiDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Gil AtzmonFaculty of Natural Sciences, University of Haifa, Haifa, Israel.
Albert Einstein College of Medicine · USRegeneron (United States) · USUniversity of Haifa · ILLeiden University Medical Center · NL

Funding

Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY E. PESSIN · 2015 to 2026
$27.7M
Validation and characterization of the identified variants associated with human longevity in mouse modelsU19AG056278 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Zhengdong Zhang · 2017 to 2026
$24.5M
Einstein's Nathan Shock Center of Excellence in Basic Biology of AgingP30AG038072 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HUFFMAN, DEREK MAJOR · 2010 to 2024
$10.8M
Resilience to Alzheimer's disease in humans with exceptional longevityR01AG057909 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BARZILAI, NIR J, ZHANG, ZHENGDONG · 2017 to 2021
$6.2M
LGP/LongenityR01AG046949 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BARZILAI, NIR J · 2013 to 2017
$2.4M
Epigenetic Profiling in Healthy Aging and Exceptional LongevityR01AG042188 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ATZMON, GIL, BARZILAI, NIR J · 2011 to 2015
$2.0M
Effect of longevity genomes on the GH/IGF-1 phenotype and disease-free survivalK23AG051148 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI MILMAN, SOFIYA · 2015 to 2018
$791k
NIA NIH HHS K23 AG051148NIA NIH HHS P30 AG038072NIA NIH HHS R01 AG042188NIA NIH HHS R01 AG046949NIA NIH HHS R01 AG057909NIA NIH HHS U19 AG056278NIDDK NIH HHS P30 DK020541
6 · The paper itself

Abstract

Centenarians (exceptionally long-lived individuals-ELLI) are a unique segment of the population, exhibiting long human lifespan and healthspan, despite generally practicing similar lifestyle habits as their peers. We tested disease-associated mutation burden in ELLI genomes by determining the burden of pathogenic variants reported in the ClinVar and HGMD databases using data from whole exome sequencing (WES) conducted in a cohort of ELLI, their offspring, and control individuals without antecedents of familial longevity (n = 1879), all descendent from the founder population of Ashkenazi Jews. The burden of pathogenic variants did not differ between the three groups. Additional analyses of variants subtypes and variant effect predictor (VEP) biotype frequencies did not reveal a decrease of pathogenic or loss-of-function (LoF) variants in ELLI and offspring compared to the control group. Case-control pathogenic variants enrichment analyses conducted in ELLI and controls also did not identify significant differences in any of the variants between the groups and polygenic risk scores failed to provide a predictive model. Interestingly, cancer and Alzheimer's disease-associated variants were significantly depleted in ELLI compared to controls, suggesting slower accumulation of mutation. That said, polygenic risk score analysis failed to find any predictive variants among the functional variants tested. The high similarity in the burden of pathogenic variation between ELLI and individuals without familial longevity supports the notion that extension of lifespan and healthspan in ELLI is not a consequence of pathogenic variant depletion but rather a result of other genomic, epigenomic, or potentially nongenomic properties.

Indexed as

Aged, 80 and overCase-Control StudiesFemaleGenetic VariationHumansLongevityMale

Identifiers

PMID32860726
PMCPMC7576295
OpenAlexW3082469975

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.